Skip to content
10-Q

Quarterly Report

Coherus Oncology, Inc. CHRS

0001104659-26-058703

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 154.25M sh
Shares Diluted Q1 2026 · Mar 31, 2026 136.4M sh
Shares Diluted Q1 2026 · Mar 31, 2025 115.86M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$57.89M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$25.83M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $115.24M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $88.88M
Stockholders Equity Q1 2026 · Mar 31, 2026 $78.62M
Stockholders Equity Q1 2026 · Dec 31, 2025 $61.01M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$183.47M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$131.99M
Current Liabilities Q1 2026 · Mar 31, 2026 $132.33M
Current Liabilities Q1 2026 · Dec 31, 2025 $140.39M
Total Liabilities Q1 2026 · Mar 31, 2026 $187.4M
Total Liabilities Q1 2026 · Dec 31, 2025 $197.33M
Current Assets Q1 2026 · Mar 31, 2026 $206.04M
Current Assets Q1 2026 · Dec 31, 2025 $206.71M
Total Assets Q1 2026 · Mar 31, 2026 $266.02M
Total Assets Q1 2026 · Dec 31, 2025 $258.34M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.28
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.49
Eps Basic Q1 2026 · Mar 31, 2026 −$0.28
Eps Basic Q1 2026 · Mar 31, 2025 −$0.49
Sga Expense Q1 2026 · Mar 31, 2026 $23.1M
Sga Expense Q1 2026 · Mar 31, 2025 $26.03M
Rd Expense Q1 2026 · Mar 31, 2026 $21.54M
Rd Expense Q1 2026 · Mar 31, 2025 $24.36M
Net Income Q1 2026 · Mar 31, 2026 −$38.33M
Net Income Q1 2026 · Mar 31, 2025 −$56.57M
Operating Income Q1 2026 · Mar 31, 2026 −$36.15M
Operating Income Q1 2026 · Mar 31, 2025 −$45.44M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $3.81M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $2.65M